- Home
- CRF vs HROW Comparison
CRF vs HROW Comparison
Compare CRF & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | HROW |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.7B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRF | HROW |
|---|---|---|
| Price | $7.27 | $36.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $71.14 |
| AVG Volume (30 Days) | ★ 1.5M | 870.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.68 |
| Revenue Next Year | N/A | $40.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.81 | $20.85 |
| 52 Week High | $8.25 | $54.98 |
Technical Indicators
Market Signals| Indicator | CRF | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 31.83 |
| Support Level | $6.76 | $36.23 |
| Resistance Level | $8.04 | $40.64 |
| Average True Range (ATR) | 0.17 | 2.72 |
| MACD | 0.01 | -1.69 |
| Stochastic Oscillator | 52.59 | 15.76 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.